Message from the Executive Director

Reflecting on Usona’s journey the past ten years since our founding, we are enlivened with a strong sense of optimism and determination to achieve our goals. Our collaborative efforts to advance scientific research, provide educational programs, and explore novel therapeutic approaches for mental health have positioned Usona with a strong foundation for the future.

As we progress through 2024, we are grateful for your support, which continues to be the driving force behind Usona Institute’s endeavors. Our mutual commitment to the convergence of science and human well-being propels us toward innovative solutions that hold the potential to create a positive impact on a global scale.

Looking back at our achievements, it's evident that together, we've made significant progress. The forthcoming report spotlights the remarkable milestones of 2023, showcasing the pivotal role played by our partners, supporters, scientific collaborators, and the passionate members of our team, all aligned towards a common mission – to provide access to affordable, effective, and safe new treatment options to those in greatest need.

Highlights

• With the publication of our Phase 2 study for psilocybin in Major Depressive Disorder (MDD), we are proceeding with a Phase 3 (PSIL301) launch in early 2024.

• We have successfully completed the first-in-human Phase 1 study for 5-MeO-DMT and are in planning for Phase 2 efficacy studies.

• The Investigational Drug Supply Program and Medicinal Chemistry team supported global research within clinical and non-clinical programs, emphasizing our commitment to advancing scientific and therapeutic understanding psychedelic molecules.

• We continue to build for the future. This, year we opened the doors to the Usona campus, a purpose-designed, vibrant space to foster collaboration, education, training, and synergy.

• Training and education programs continue to expand in support of our clinical development and external education initiatives. We hosted three immersive educational programs and expanded the clinical therapeutics team to support our development programs and in preparation for future delivery of care.

As we navigate the exciting years ahead, your continued support is crucial as we work toward advancing our goals and making a meaningful difference in the lives of many.

Together, we look forward to the possibilities that the future holds and the transformative impact we can achieve.

With deep gratitude,